Navigation Links
First tests of old patent medicine remedies from a museum collection
Date:4/7/2013

NEW ORLEANS, April 7, 2013 What was in Dr. F. G. Johnson's French Female Pills and other scientifically untested elixirs, nostrums and other quack cures that were the only medicines available to sick people during the 18th, 19th and early 20th centuries?

Scientists provided a glimpse today based on an analysis of a museum collection of patent medicines used in turn-of-the-century America. It was part of the 245th National Meeting & Exposition of the American Chemical Society, the world's largest scientific society, which is being held here this week.

Mark Benvenuto, Ph.D, who headed the study, explained that hundreds of untested products were sold in stores, by mail order or in traveling medicine shows during the patent medicine era. The products were called "patent medicines" not because they had been granted a government patent, but from an unrelated term that originated in 17th century England.

"This was an era long before the controlled clinical trials and federal regulations that ensure the safety and effectiveness of the medicines we take today," Benvenuto explained. "Many patent medicines had dangerous ingredients, not just potentially toxic substances like arsenic, mercury and lead, but cocaine, heroin and high concentrations of alcohol."

The samples came from the collection of the Henry Ford Museum, in Dearborn, Mich. The museum houses artifacts celebrating American inventors of various items, including planes, cars, trains, machines, furniture and more. The 50 patent medicines in the analysis were among hundreds in the museum's Health Aids collection. The results of Benvenuto's study are on display at the museum.

Undergraduate students working under Benvenuto's supervision performed the bulk of the research. Andrew Diefenbach, a senior and mechanical engineering major at the university, presented the group's research in a talk here today. He got involved in the project as a freshman in Benvenuto's g
'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
504-670-4707 (New Orleans Press Center, April 5-10)
202-872-6042

Michael Woods
m_woods@acs.org
504-670-4707 (New Orleans Press Center, April 5-10)
202-872-6293

American Chemical Society


Source:Eurekalert

Page: 1 2

Related biology news :

1. Kessler Foundation implements Ekso Bionics first commercial robotic exoskeleton
2. Research reveals first evidence of hunting by prehistoric Ohioans
3. First model of how buds grow into leaves
4. American College of Rheumatology releases first classification criteria for polymyalagia rheumatica
5. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
6. First complete full genetic map of promising energy crop
7. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
8. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
9. New technology tracks sparrow migration for first time from California to Alaska
10. First mass extinction linked to marine anoxia
11. Scientists complete first-ever emperor penguin count from space
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ...  report to their offering. One major ... With continuous advances in technology, it is important to ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... , PITTSBURGH, Feb. 13, 2014 University of Pittsburgh ... be able to do new tricks., By screening a library ... as a treatment for a rare type of cancer, UPCI ... try if the cancer becomes resistant to standard drug treatment., ...
... Children,s Hospital of Philadelphia (CHOP) have developed a ... encode HLA molecules. The test relies on faster, ... leukocyte antigens (HLAs)--complex, highly variable proteins on cell ... The new test may improve transplantation outcomes through ...
... has been named a Fellow of the American Association ... the field of global change ecology, particularly for pioneering ... Models or forecasts similar to those produced for ... the environment will alter an entire ecosystem in the ...
Cached Biology News:Laboratory detective work points to potential therapy for rare, drug-resistant cancer 2CHOP introduces HLA typing by next-generation sequencing to its clinical services 2CHOP introduces HLA typing by next-generation sequencing to its clinical services 3
(Date:1/22/2015)... Jan. 22, 2015  Transwestern | RBJ today announces the firm ... space for Shire a leading biopharmaceutical company, at Two Ledgemont ... RBJ,s Robert Richards , president, and Brian Cohen ... the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... 22, 2015 Protocol Networks brings independent ... team of brand-neutral, independent consultants, Protocol Networks has recently ... that over the years, his company has attracted several ... of Plainfield, as well as others. With the success ...
(Date:1/22/2015)... 22, 2015 zFlo Motion , a ... announce an exciting product from a new partner. STT-Systems ... over the past 15 years, with offerings in the optical-motion ... 3D IMU system (inertial measurement unit), iSen, is opening eyes ...
(Date:1/22/2015)... Switzerland (PRWEB) January 22, 2015 Selexis ... characterized mammalian Research Cell Banks (RCBs) used for drug ... Research Cell Banks will include Next-Generation Sequencing ... genetic architecture de-risks biologic manufacturing by ensuring the integrity ...
Breaking Biology Technology:Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 23D Motion Capture Just Got Easy 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... SAN DIEGO, May 17, 2011 Verenium Corporation (Nasdaq: ... focused on the development and commercialization of high-performance enzymes, ... by MDB Capital Group at the second annual Bright ...  The Bright Lights Conference is the only conference with ...
... Life Technologies Corporation (NASDAQ: LIFE ... of Gibco® Freedom™ Cell Line Development Kits , a ... media and protocols to bring simplicity and flexibility, eliminating up ... drug development.  These kits make it easier and faster to ...
... May 16, 2011 Masimo ... from a new study published in the American ... hemoglobin (SpHb®) monitoring correlates strongly with invasive laboratory hemoglobin ... and critical care setting and may potentially decrease the ...
Cached Biology Technology:Verenium Receives CLARUS Award at MDB Capital's Bright Lights Conference 2011 2Verenium Receives CLARUS Award at MDB Capital's Bright Lights Conference 2011 3Verenium Receives CLARUS Award at MDB Capital's Bright Lights Conference 2011 4Life Technologies and ProBioGen AG Announce Freedom™ Cell Line Development Royalty-Free Kits To Advance Early Stage Biologic Drug Production 2Life Technologies and ProBioGen AG Announce Freedom™ Cell Line Development Royalty-Free Kits To Advance Early Stage Biologic Drug Production 3Life Technologies and ProBioGen AG Announce Freedom™ Cell Line Development Royalty-Free Kits To Advance Early Stage Biologic Drug Production 4Life Technologies and ProBioGen AG Announce Freedom™ Cell Line Development Royalty-Free Kits To Advance Early Stage Biologic Drug Production 5New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 2New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 3New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 4New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 5New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 6
... Immunogen: Synthetic peptide derived from the ... mouse dog and orangutang occludin proteins. ... occludin protein. Reactivity: Human (positive ... with rat mouse dog and orangutang ...
...
... protein western blot (WtPAN) is ... specific protein expression in plant ... is included in each blot ... comparison between different western blots. ...
... Water is suitable for use ... by incubating with 0.1% diethylpyrocarbonate ... remove the DEPC.DNase/RNase-Free Distilled WaterDistilled ... in all molecular biology applications. ...
Biology Products: